U.S. Other Utilities Stock News

NasdaqGM:VERI
NasdaqGM:VERISoftware

A Look At Veritone (VERI) Valuation As Lawsuits And Restated Financials Pressure The Share Price

Veritone (VERI) is back in focus after multiple law firms filed class action lawsuits alleging misstatements in its financial reporting, following the company’s disclosures about overstated revenue, deficient controls, and required restatements. See our latest analysis for Veritone. Those accounting disclosures and the new US$50 million at the market offering have come against a weak backdrop, with the share price down 55.32% year to date and a 1 year total shareholder return of 22.64%...
NasdaqGS:INTA
NasdaqGS:INTASoftware

Intapp Expands AI Timekeeping As Shares Trade Below Analyst Targets

Intapp (NasdaqGS:INTA) has introduced new AI powered features in Intapp Time, focused on helping professional services firms manage time and revenue capture more efficiently. The latest release includes AI work code prediction, configurable narrative tone enforcement, and upgraded mobile timekeeping tools. The update expands the use of AI across Intapp's cloud product suite for professional services clients. Intapp operates in the professional services technology space, where firms depend...
NYSE:CTRA
NYSE:CTRAOil and Gas

A Look At Coterra Energy (CTRA) Valuation After Its Form 15 Deregistration Move

Coterra Energy (CTRA) has moved to voluntarily deregister its common stock and several senior notes by filing Form 15 with the SEC, marking a material shift in its reporting and disclosure obligations for investors. See our latest analysis for Coterra Energy. The share price has reacted sharply around these filings, with a 1-day share price return down 8.62% and a 7-day share price return down 7.97%. This follows a year-to-date share price return of 22.41% and a 1-year total shareholder...
NasdaqCM:NGEN
NasdaqCM:NGENPharmaceuticals

Assessing NervGen Pharma (NasdaqCM:NGEN) Valuation After Its $60 Million Follow On Equity Offering

NervGen Pharma (NGEN) has drawn fresh attention after completing a follow on public equity offering of approximately $60 million, including common shares and warrants, to fund its neuroreparative drug development programs. See our latest analysis for NervGen Pharma. The follow on offering has coincided with sharp share price pressure, with NervGen Pharma’s 1 day share price return down 43.48% and its year to date share price return down 64.63%. This comes even though the 5 year total...
NYSE:LUXE
NYSE:LUXESpecialty Retail

Assessing LuxExperience B.V (LUXE) Valuation After Wider Losses And YNAP And THE OUTNET Reshaping

LuxExperience B.V (LUXE) drew fresh attention after reporting third quarter and nine month results that paired higher sales with a wider net loss, while also closing the sale of THE OUTNET and outlining a YNAP transformation plan. See our latest analysis for LuxExperience B.V. The latest quarter, with higher sales but a wider loss and fresh restructuring charges, has coincided with pressure on the stock, which is down 21.31% on a 1 month share price basis and 22.53% on a 1 year total...
NasdaqGS:GENB
NasdaqGS:GENBBiotechs

Can Nvidia’s Backing Reframe Generate Biomedicines (GENB) as a Scaled AI Drug Developer?

Earlier in May 2026, Nvidia invested US$10.40 million in Generate Biomedicines, an AI-driven biotech now advancing several drug candidates through clinical development, including a Phase 3 severe asthma program and oncology therapies with FDA Fast Track status. This combination of external validation from a major AI leader and visible clinical momentum underscores how AI-enabled drug discovery is moving from concept toward real-world testing. Next, we’ll examine how Nvidia’s investment and...
NYSE:BLSH
NYSE:BLSHCapital Markets

What Bullish (BLSH)'s Massive Equiniti Deal and ARK Buying Spree Means For Shareholders

Bullish recently reported first-quarter 2026 results showing US$20.01 million in sales and a net loss of US$581.71 million, while also announcing a US$4.20 billion acquisition of Equiniti and facing widening per-share losses versus a year earlier. Amid these developments and broader digital asset volatility, ARK Invest and other institutional investors have been actively building positions in Bullish, signaling renewed institutional focus on its role in tokenization and crypto-market...
NYSE:AMBQ
NYSE:AMBQSemiconductor

A Look At Ambiq Micro (AMBQ) Valuation After A Sharp Multi Month Share Price Surge

Ambiq Micro stock: quick context on recent performance Ambiq Micro (AMBQ) has been drawing attention after sharp recent gains, with the stock up 130% over the past month and up about 172% over the past 3 months. That move comes as investors weigh a US$1.75b market value against the company’s US$81.8m in revenue and a reported net loss of US$38.3m from its ultra low power semiconductor business. See our latest analysis for Ambiq Micro. At a share price of US$81.67, Ambiq Micro’s recent surge,...
NYSE:BG
NYSE:BGFood

Bunge Global Dividend Increase And Valuation Gap Catch Investor Attention

Shareholders of Bunge Global (NYSE:BG) approved an increase to the company’s cash dividend at its 2026 Annual General Meeting. The decision confirms a higher level of cash distributions to shareholders compared with the prior dividend. The outcome of the 2026 AGM highlights management’s current approach to capital returns alongside other corporate priorities. Bunge Global operates as an agribusiness and food company, connecting farmers and end markets across crop processing, ingredients,...